Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial

Watchlist | Portfolio | Dashboard

Faster, Cleaner, Better.

Nkgen Biotech Inc (NKGN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]

[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]

[[ session ]] by (Cboe BZX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]

[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]

[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]

Cash Flow for [[ item.sessionDateDisplayLong ]]

Fiscal Year End Date: 12/31

(Values in U.S. thousands)

	12-2024	12-2023	12-2022	12-2021	12-2017
Cash Flows From Operating Activities
Net Income	-44,286	-82,954	-26,754	-991	N/A
Depreciation Amortization	1,315	1,203	1,210	N/A	N/A
Accounts receivable	N/A	29	-29	N/A	N/A
Accounts payable and accrued liabilities	2,263	3,993	443	52	N/A
Other Working Capital	1,374	2,226	30	982	N/A
Other Operating Activity	18,453	53,555	2,543	-1,566	0
Operating Cash Flow	$-20,881	$-21,948	$-22,557	$-1,524	$N/A

Cash Flows From Investing Activities
PPE Investments	-13	-48	-163	N/A	N/A
Purchase Of Investment	N/A	N/A	N/A	-171,615	N/A
Investing Cash Flow	$-13	$-48	$-163	$-171,615	$N/A

Cash Flows From Financing Activities
Debt Issued	19,395	26,506	23,000	1	N/A
Debt Repayment	-1,116	-300	N/A	-70	N/A
Common Stock Issued	350	11,890	161	N/A	N/A
Other Financing Activity	2,224	-15,941	-675	174,931	0
Financing Cash Flow	$20,853	$22,155	$22,486	$174,861	$N/A

Beginning Cash Position	276	117	351	N/A	N/A
End Cash Position	235	276	117	1,723	N/A
Net Cash Flow	$-41	$159	$-234	$1,723	$N/A

Free Cash Flow
Operating Cash Flow	-20,881	-21,948	-22,557	-1,524	N/A
Capital Expenditure	-48	-48	-163	N/A	N/A
Free Cash Flow	-20,929	-21,996	-22,720	-1,524	0